"Paxlovid's Limited Impact on Vaccinated COVID-19 Patients Revealed in Study"

A study in the New England Journal of Medicine found that the antiviral drug Paxlovid did not significantly reduce symptom duration for fully vaccinated individuals with at least one risk factor for severe COVID-19. The trial included 1,296 participants and showed no significant difference in symptom alleviation between those who took Paxlovid and those who took a placebo. Experts caution that the findings might not apply to older, high-risk populations and suggest that longer-term studies on Paxlovid are needed to assess its potential benefits, particularly for those at highest risk for disease progression.